Abstract
Dysfunction in or lack of osteoclasts result in osteopetrosis, a group of rare but often severe, genetic disorders characterized by an increase in bone mass, skeletal malformations and bone marrow failure that may be fatal. Several of the underlying defects have lately been characterized in humans and in animal disease models. In humans, these defects often involve mutations in genes expressing proteins involved in the acidification of the osteoclast sub-cellular compartment, a process necessary for proper bone resorption. So far, the only cure for children with severe osteopetrosis is allogeneic hematopoietic stem cell transplantation (SCT). However, the characterization of the genetic defects opens up the possibility for gene replacement therapy as an alternative to SCT. Recently, gene therapy targeting hematopoietic stem cells (HSC) in a mouse model of infantile malignant osteopetrosis was shown to correct many aspects of the disease. Here we review important aspects of this group of diseases and discuss the prospects for development of gene therapy of osteopetrosis.
Keywords: Osteoclast, osteoblast, bone remodelling, viral vector, stem cell transplantation, hematopoietic stem cell, engraftment, oc/oc mouse
Current Gene Therapy
Title: Prospects for Gene Therapy of Osteopetrosis
Volume: 9 Issue: 3
Author(s): Maria Askmyr, Carmen Flores, Anders Fasth and Johan Richter
Affiliation:
Keywords: Osteoclast, osteoblast, bone remodelling, viral vector, stem cell transplantation, hematopoietic stem cell, engraftment, oc/oc mouse
Abstract: Dysfunction in or lack of osteoclasts result in osteopetrosis, a group of rare but often severe, genetic disorders characterized by an increase in bone mass, skeletal malformations and bone marrow failure that may be fatal. Several of the underlying defects have lately been characterized in humans and in animal disease models. In humans, these defects often involve mutations in genes expressing proteins involved in the acidification of the osteoclast sub-cellular compartment, a process necessary for proper bone resorption. So far, the only cure for children with severe osteopetrosis is allogeneic hematopoietic stem cell transplantation (SCT). However, the characterization of the genetic defects opens up the possibility for gene replacement therapy as an alternative to SCT. Recently, gene therapy targeting hematopoietic stem cells (HSC) in a mouse model of infantile malignant osteopetrosis was shown to correct many aspects of the disease. Here we review important aspects of this group of diseases and discuss the prospects for development of gene therapy of osteopetrosis.
Export Options
About this article
Cite this article as:
Askmyr Maria, Flores Carmen, Fasth Anders and Richter Johan, Prospects for Gene Therapy of Osteopetrosis, Current Gene Therapy 2009; 9 (3) . https://dx.doi.org/10.2174/156652309788488613
DOI https://dx.doi.org/10.2174/156652309788488613 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroinflammation and Immunity: A New Pharmacological Target in Depression
CNS & Neurological Disorders - Drug Targets Imaging Primary Brain Tumors by Single-Photon Emission Computerized Tomography (SPECT) with Technetium-99m Sestamibi (MIBI) and Tetrofosmin
Current Medical Imaging Relationship Between Body Mass Index and Reproduction
Current Women`s Health Reviews Hepatoblastoma: Review of Pathology, Diagnosis and Modern Treatment Strategies
Current Cancer Therapy Reviews Anti-metastatic Treatment in Colorectal Cancer: Targeting Signaling Pathways
Current Pharmaceutical Design The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism Pharmacogenomics of Open-Angle Glaucoma
Current Pharmacogenomics and Personalized Medicine Systematic Evaluation of Drug-Loaded Hydrogels for Application in Osteosarcoma Treatment
Current Pharmaceutical Biotechnology Effect of Radio Frequency Waves of Electromagnetic Field on the Tubulin
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Gene Expression Profiles of Medulloblastoma Cell Lines Resistant to Preactivated Cyclophosphamide
Current Cancer Drug Targets Zebrafish as a Model System to Screen Radiation Modifiers
Current Genomics Primary Tumors of the Sacrum: Imaging Findings
Current Medical Imaging Arterial Thickness and Immunometabolism: The Mediating role of Chronic Exercise
Current Cardiology Reviews Posaconazole: A New Antifungal Weapon
Reviews on Recent Clinical Trials High Dose Immunoglobulin (IVIG) May Reduce the Incidence of Langerhans Cell Histiocytosis (LCH)-Associated Central Nervous System Involvement
CNS & Neurological Disorders - Drug Targets FK506 Binding Proteins as Targets in Anticancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Biologics for Extraintestinal Manifestations of IBD
Current Drug Targets Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews Hedgehog Signaling and Urological Cancers
Current Drug Targets The Role for Oxidative Stress in Aberrant DNA Methylation in Alzheimer’s Disease
Current Alzheimer Research